Clinical Trial Update: An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options [Phase 3]

View source ↗

Summary

Phase 3 expanded-access program in China evaluating Spesolimab for generalized pustular psoriasis in patients with no other treatment options, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• SPESOLIMAB (BI655130)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Generalized Pustular Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2024-10-09